Deerfield Management owned Endologix has acquired medical technology company PQ Bypass to bolster vascular reach to treat unmet medical needs of both abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD) patients.
Deerfield Management owned Endologix has acquired medical technology company PQ Bypass to bolster vascular reach to treat unmet medical needs of both abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD) patients.
PQ Bypass focuses on making new advancements in PAD treatment.
Endologix CEO and chairman Richard Mott said: “The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease.
“We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”
Deerfield Management partner Andrew ElBardissi said: “We are excited about the progress that Endologix has made over the past year.
“With the acquisition of PQ Bypass, we believe the company is positioned to accelerate its leadership in the treatment of vascular disease, and we look forward to supporting continued growth.”
The companies have not divulged the financial details of the deal.
Last September, the Detour System of PQ Bypass received the US Food & Drug Administration Breakthrough Device designation.
